{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036944","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.390295+00:00","generated_at":"2026-05-31T09:36:41.931848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocuphire Q2 net loss $7.8M ($0.30/sh); cash $41.4M; VEGA-3 recruiting for presbyopia","bullets":["Net loss $7.8M ($0.30/sh) vs $5.0M ($0.24) in Q2 2023; revenue from collaborator license $1.1M vs $3.7M.","Cash $41.4M provides runway into mid-2025; R&D spend $6.1M (+30% YoY) driven by APX3330 manufacturing.","VEGA-3 Phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia now recruiting; topline 2025.","LYNX-2 Phase 3 study for dim light disturbances enrollment strong; LYNX-3 study planned for 2024.","Discussions with FDA ongoing for APX3330 Special Protocol Assessment in diabetic retinopathy."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036944","json":"https://secwatch.observer/filing/0001140361-24-036944.json","markdown":"https://secwatch.observer/filing/0001140361-24-036944.md","text":"https://secwatch.observer/filing/0001140361-24-036944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124036944/0001140361-24-036944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124036944/ef20033986_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:36:41.931848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}